期刊文献+

质子泵抑制药和H2受体拮抗药预防应激性溃疡有效性和安全性的Meta分析 被引量:8

Efficacy and safety of proton pump inhibitors and Histamine-2-receptor antagonists for stress ulcer prophylaxis in critically ill patients: a meta-analysis of randomized trials
在线阅读 下载PDF
导出
摘要 目的比较质子泵抑制药(proton pump inhibitors,PPI)和H2受体拮抗药(histamine-2-receptor antagonists,H2RAs)预防危重患者应激性溃疡的有效性和安全性。方法对Cochrane图书馆,Pub Med,Embase,Science Direct数据库,中国知网,中国生物医学文献数据库进行检索。只纳入PPI和H2RA预防应激性溃疡的随机对照(RCT)实验进行Meta分析,统计指标包括临床消化道大出血,明显上消化道出血,医源性肺炎,死亡率,ICU住院时间,艰难梭菌感染。结果纳入9篇文献,其中高质量文献3篇,共报道消化道大出血患者1151例,结果表明预防性应用PPI与H2RA相比,可以降低临床胃肠道大出血的风险(RR=0. 39;95%CI=0. 21-0. 71;P=0. 002;I^2=0%)。结论应用PPI预防应激性溃疡效果要优于H2RA,可以降低消化道大出血和明显上消化道出血的风险,同时未增加肺炎风险、死亡率和ICU住院时间。两药对艰难梭菌感染的影响尚不明确。 Objective To compare the curative effect and safety of proton pump inhibitors( PPI) and histamine-2-receptor antagonists( H2RAs) when used to prevent stress ulcer prophylaxis in critically ill patients. Methods Randomized controlled trials( RCTs) of PPI vs H2RA for stress ulcer prophylaxis in patients in critical condition were retrieved from the Cochrane library,Pub Med,Embase,Science Direct,CNKI and CMB databases. Key indexes included gastrointestinal( GI) bleeding,iatrogenic pneumonia,Clostridium difficile infection,mortality and length of stay in the ICU. Results Prophylactic application of PPIs can reduce the risk of clinical gastrointestinal bleeding and upper gastrointestinal bleeding compared with H2RA. Conclusions PPIs are superior to H2RAs in preventing GI bleeding without significantly increasing the risk of pneumonia or mortality. However,their impact on Clostridium difficile infections remains uncertain.
作者 张虹 苑键 于向丽 叶林 杨春梅 ZHANG Hong;YUAN Jian;YU Xiangli;YE lin;YANG Chunmei(Outpatient Department, the Third Medical Center of PLA General Hospital,Beijing100039 ,China)
出处 《武警医学》 CAS 2019年第6期510-512,517,共4页 Medical Journal of the Chinese People's Armed Police Force
关键词 质子泵抑制剂 H2受体拮抗剂 应激性溃疡 META分析 proton pump inhibitor histamine-2-receptor antagonist stress ulcer meta-analysis
  • 相关文献

参考文献1

二级参考文献10

  • 1[1]Johanson JF, Siddique R, Damiano AM, Jokubaitis L,Murthy A, Bhattacharjya A. Rabeprazole improves healthelated quality of life in patients with erosive gastroesophageal reflux disease. Dig Dis Sci, 2002, 47: 2574~2578.
  • 2[2]Skoczylas T, Sarosiek l, Sostarich S, McElhinney C, Durham S, Sarosiek J. Significant enhancement of gastric mucin content after rabeprazole administration: its poten tial clinical significance in acid-related disorders. Dig DisSci, 2003, 48: 322~328.
  • 3[3]Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE Ⅱ: a severity of disease classification system. Crit Care Med, 1985, 13: 818~829.
  • 4[4]Ranson JH, Rifkind KM, Roses DF, Fink SD, Eng K, Spencer FC. Prognostic signs and the role of operative management in acute pancreatitis. Surg Gynecol Obstet, 1974, 139: 69~81.
  • 5[5]Balthazar EJ, Robinson DL, Megibow AJ, Ranson JH. Acute pancreatitis: value of CT in establishing prognosis. Radiology, 1990, 174: 331~336.
  • 6[6]Lin CK, Wang ZS, Lai KH, Lo GH, Hsu PI. Gastrointestinal mucosal lesions in patients with acute pancreati tis. Zhonghua Yi Xue Za Zhi (Taipei), 2002, 65: 275~ 278.
  • 7[7]Tryba M. Role of acid suppressants in intensive care medic ine. Best Pract Res Clin Gastroenterol, 2001, 15: 447~461.
  • 8[8]Steinberg KP. Stress-related mucosal disease in the crit ically ill patient: risk factors and strategies to prcvent stress-related bleeding in the intensive care unit. Crit Care Med, 2002, 30 (6 Suppl): S362~S364.
  • 9[9]Freedman MD. Stress ulcer prevention and histamine-2 receptor antagonists: leaps of faith or back to the drawing board? Crit Care Med, 1999, 27: 13~14.
  • 10[10]Saitoh T, Fukushima Y, Otsuka H, Hirakawa J, Mori H, Asano T, Ishikawa T, Katsube T, Ogawa K, Ohkawa S.Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment Pharmacol Ther, 2002, 16:1811~1817.

共引文献14

同被引文献137

引证文献8

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部